EMBER 4/J2J-MC-JZLH
«EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence»
ΕΝΕΡΓΟ RECRUITMENT
Έναρξη Μελέτης: 30 Αυγούστου 2022
Λήξη Μελέτης: 3 Μαρτίου 2032